Moderna (MRNA) has surged 94% in 2026 so far, crushing Pfizer (PFE) at just +4% and beating Novavax (NVAX) at +41%, as Moderna's leadership restructuring has signaled a 2027-2028 product launch push.

Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were both leaders in the coronavirus vaccine market. However, as sales of these products have declined significantly in recent years -- due to the ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. The year-to-date scoreboard tells the same story. Moderna ...

When COVID-19 vaccines were being developed, manufacturers had to hit an efficacy rate of 50 per cent before their jabs could get approval. Most vaccines now in common use exceeded expectations, with ...

Tue, June 16, 2026 at 7:21 PM UTC Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the ...